Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Parkinson's Disease

  Free Subscription


Articles published in J Neurochem

Retrieve available abstracts of 48 articles:
HTML format



Single Articles


    March 2020
  1. KATAURA T, Shinji S, Ishikawa KI, Akamatsu W, et al
    BRUP-1, an intracellular bilirubin modulator, exerts neuroprotective activity in a cellular Parkinson's disease model.
    J Neurochem. 2020 Mar 3. doi: 10.1111/jnc.14997.
    PubMed     Abstract available


    January 2020
  2. SANPHUI P, Das AK, Biswas SC
    FoxO3a requires BAF57, a subunit of chromatin remodeler SWI/SNF complex for induction of PUMA in a model of Parkinson's disease.
    J Neurochem. 2020 Jan 23:e14969. doi: 10.1111/jnc.14969.
    PubMed     Abstract available


    November 2019
  3. COGO S, Manzoni C, Lewis PA, Greggio E, et al
    Leucine-rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease.
    J Neurochem. 2019 Nov 6. doi: 10.1111/jnc.14908.
    PubMed     Abstract available


    October 2019
  4. CORREIA GUEDES L, Mestre T, Outeiro TF, Ferreira JJ, et al
    Are genetic and idiopathic forms of Parkinson's disease the same disease?
    J Neurochem. 2019 Oct 23. doi: 10.1111/jnc.14902.
    PubMed     Abstract available


    September 2019
  5. LI T, Zhang W, Kang X, Yang R, et al
    Salidroside Protects Dopaminergic Neurons by Regulating the Mitochondrial MEF2D-ND6 Pathway in the MPTP/MPP(+) -Induced Model of Parkinson's Disease.
    J Neurochem. 2019 Sep 14. doi: 10.1111/jnc.14868.
    PubMed     Abstract available


  6. OUTEIRO TF, Mestre TA
    Synuclein Meeting 2019: where we are and where we need to go.
    J Neurochem. 2019;150:462-466.
    PubMed     Abstract available


  7. WASSOUF Z, Schulze-Hentrich JM
    Alpha-synuclein at the nexus of genes and environment: the impact of environmental enrichment and stress on brain health and disease.
    J Neurochem. 2019;150:591-604.
    PubMed     Abstract available


  8. KILLINGER BA, Kordower JH
    Spreading of alpha-synuclein - relevant or epiphenomenon?
    J Neurochem. 2019;150:605-611.
    PubMed     Abstract available


  9. GONZALEZ N, Arcos-Lopez T, Konig A, Quintanar L, et al
    Effects of alpha-synuclein post-translational modifications on metal binding.
    J Neurochem. 2019;150:507-521.
    PubMed     Abstract available


  10. STEFANIS L, Emmanouilidou E, Pantazopoulou M, Kirik D, et al
    How is alpha-synuclein cleared from the cell?
    J Neurochem. 2019;150:577-590.
    PubMed     Abstract available


  11. VAIKATH NN, Hmila I, Gupta V, Erskine D, et al
    Antibodies against alpha-synuclein: tools and therapies.
    J Neurochem. 2019;150:612-625.
    PubMed     Abstract available


    August 2019
  12. LIU H, Wu H, Zhu N, Xu Z, et al
    Lactoferrin protects against iron dysregulation, oxidative stress, and apoptosis in MPTP-induced Parkinson's disease in mice.
    J Neurochem. 2019 Aug 23. doi: 10.1111/jnc.14857.
    PubMed     Abstract available


  13. SORGDRAGER FJH, Vermeiren Y, Van Faassen HJR, Van Der Ley CP, et al
    Age- and Disease-Specific Changes of the Kynurenine Pathway in Parkinson's and Alzheimer's Disease.
    J Neurochem. 2019 Aug 3. doi: 10.1111/jnc.14843.
    PubMed     Abstract available


  14. BOONYING W, Joselin A, Huang E, Qu D, et al
    Pink1 regulates FKBP5 interaction with AKT/PHLPP and protects neurons from neurotoxin stress induced by MPP(.)
    J Neurochem. 2019;150:312-329.
    PubMed     Abstract available


    July 2019
  15. VIDYADHARA DJ, Lee JE, Chandra SS
    Role of the Endolysosomal System in Parkinson's disease.
    J Neurochem. 2019 Jul 9. doi: 10.1111/jnc.14820.
    PubMed     Abstract available


  16. SULZER D, Edwards RH
    The Physiological Role of alpha-Synuclein and Its Relationship to Parkinson's Disease.
    J Neurochem. 2019 Jul 3. doi: 10.1111/jnc.14810.
    PubMed     Abstract available


  17. FAYYAD M, Salim S, Majbour N, Erskine D, et al
    Parkinson's Disease Biomarkers based on Alpha-synuclein.
    J Neurochem. 2019 Jul 2. doi: 10.1111/jnc.14809.
    PubMed     Abstract available


    May 2019
  18. HUANG W, Xu Y, Zhang Y, Zhang P, et al
    Metabolomics-driven identification of adenosine deaminase as therapeutic target in a mouse model of Parkinson's disease.
    J Neurochem. 2019 May 23. doi: 10.1111/jnc.14774.
    PubMed     Abstract available


    April 2019
  19. LI Y, Cookson MR
    Proteomics; applications in familial Parkinson's disease.
    J Neurochem. 2019 Apr 25. doi: 10.1111/jnc.14708.
    PubMed     Abstract available


  20. DINIZ LP, Matias I, Araujo APB, Garcia MN, et al
    alpha-synuclein oligomers enhance astrocyte-induced synapse formation through TGF-beta1 signaling in a Parkinson's disease model.
    J Neurochem. 2019 Apr 22. doi: 10.1111/jnc.14710.
    PubMed     Abstract available


  21. MOLLENHAUER B, Bowman FD, Drake D, Duong J, et al
    Antibody-based methods for the measurement of alpha-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study.
    J Neurochem. 2019;149:126-138.
    PubMed     Abstract available


    March 2019
  22. WALKER L, Stefanis L, Attems J
    Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies - current issues and future directions.
    J Neurochem. 2019 Mar 20. doi: 10.1111/jnc.14698.
    PubMed     Abstract available


  23. FANG X, Tian P, Zhao X, Jiang C, et al
    Neuroprotective effects of an engineered commensal bacterium in the MPTP Parkinson disease mouse model via producing GLP-1.
    J Neurochem. 2019 Mar 9. doi: 10.1111/jnc.14694.
    PubMed     Abstract available


    February 2019
  24. BILLINGS JL, Gordon SL, Rawling T, Doble PA, et al
    L-DOPA modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.
    J Neurochem. 2019 Feb 4. doi: 10.1111/jnc.14676.
    PubMed     Abstract available


    November 2018
  25. CILENTO EM, Jin L, Stewart T, Shi M, et al
    Mass Spectrometry: A Platform for Biomarker Discovery and Validation for Alzheimer's and Parkinson's Diseases.
    J Neurochem. 2018 Nov 26. doi: 10.1111/jnc.14635.
    PubMed     Abstract available


    September 2018
  26. HARRISON IF, Powell NM, Dexter DT
    The Histone Deacetylase Inhibitor Nicotinamide Exacerbates Neurodegeneration in the Lactacystin Rat Model of Parkinson's Disease.
    J Neurochem. 2018 Sep 30. doi: 10.1111/jnc.14599.
    PubMed     Abstract available


    August 2018
  27. KOMNIG D, Dagli CT, Habib P, Zeyen T, et al
    Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson disease and does not lead to a sustainable increase of brain BDNF.
    J Neurochem. 2018 Aug 28. doi: 10.1111/jnc.14575.
    PubMed     Abstract available


  28. GALLEA JI, Ambroggio EE, Vilcaes AA, James NG, et al
    Amyloid oligomerization of the Parkinson's disease related protein alpha-synuclein impacts on its curvature-membrane sensitivity.
    J Neurochem. 2018 Aug 24. doi: 10.1111/jnc.14573.
    PubMed     Abstract available


    June 2018
  29. BACH JP, Falkenburger BH
    What autoantibodies tell us about the pathogenesis of Parkinson's disease: An Editorial for 'Measurements of auto-antibodies to alpha-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease' on doi: 10.1111/jnc.14330.
    J Neurochem. 2018 Jun 6. doi: 10.1111/jnc.14340.
    PubMed    


    April 2018
  30. ANGELOPOULOU E, Piperi C, Papavassiliou AG
    High-mobility Group Box 1 in Parkinson's disease: from pathogenesis to therapeutic approaches.
    J Neurochem. 2018 Apr 20. doi: 10.1111/jnc.14450.
    PubMed     Abstract available


  31. SPAY C, Albares M, Lio G, Thobois S, et al
    Clonidine modulates the activity of the subthalamic-supplementary motor loop: evidence from a pharmacological study combining DBS and EEG recordings in Parkinsonian patients.
    J Neurochem. 2018 Apr 20. doi: 10.1111/jnc.14447.
    PubMed     Abstract available


    March 2018
  32. AKHTAR RS, Licata JP, Luk KC, Shaw LM, et al
    Measurements of auto-antibodies to alpha-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease.
    J Neurochem. 2018 Mar 3. doi: 10.1111/jnc.14330.
    PubMed     Abstract available


    February 2018
  33. MAASS F, Michalke B, Leha A, Boerger M, et al
    Elemental fingerprint as a cerebrospinal fluid biomarker for the diagnosis of Parkinson's disease.
    J Neurochem. 2018 Feb 1. doi: 10.1111/jnc.14316.
    PubMed     Abstract available


    January 2018
  34. ZHANG J, Culp ML, Craver JG, Darley-Usmar V, et al
    Mitochondrial function and autophagy: integrating proteotoxic, redox, and metabolic stress in Parkinson's disease.
    J Neurochem. 2018 Jan 17. doi: 10.1111/jnc.14308.
    PubMed     Abstract available


  35. XU S, Yang X, Qian Y, Xiao Q, et al
    Parkinson disease-related DJ-1 modulates the expression of uncoupling protein 4 against oxidative stress.
    J Neurochem. 2018 Jan 8. doi: 10.1111/jnc.14297.
    PubMed     Abstract available


    December 2017
  36. BRACZYNSKI AK, Schulz JB, Bach JP
    Vaccination strategies in tauopathies and synucleinopathies.
    J Neurochem. 2017;143:467-488.
    PubMed     Abstract available


    November 2017
  37. JOSEPH S, Schulz JB, Stegmuller J
    Mechanistic contributions of FBXO7 to Parkinson's disease.
    J Neurochem. 2017 Nov 14. doi: 10.1111/jnc.14253.
    PubMed     Abstract available


    August 2017
  38. MYTHRI RB, Raghunath NR, Narwade SC, Pandareesh MD, et al
    Manganese and 1-methyl-4-phenylpyridinium (MPP+ ) induced neurotoxicity indicate differences in morphological, electrophysiological and genome-wide alterations: Implications for idiopathic Parkinson's disease.
    J Neurochem. 2017 Aug 12. doi: 10.1111/jnc.14147.
    PubMed     Abstract available


  39. DAS BANERJEE T, Dagda RY, Dagda M, Chu CT, et al
    PINK1 regulates mitochondrial trafficking in dendrites of cortical neurons through mitochondrial PKA.
    J Neurochem. 2017;142:545-559.
    PubMed     Abstract available


    June 2017
  40. HAVELUND JF, Andersen AD, Binzer M, Blaabjerg M, et al
    Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia.
    J Neurochem. 2017 Jun 19. doi: 10.1111/jnc.14104.
    PubMed     Abstract available


    May 2017
  41. LEIKAS JV, Kohtala S, Theilmann W, Jalkanen AJ, et al
    Brief isoflurane anesthesia regulates striatal AKT-GSK3beta signaling and ameliorates motor deficits in a rat model of early-stage Parkinson's disease.
    J Neurochem. 2017 May 10. doi: 10.1111/jnc.14066.
    PubMed     Abstract available


    April 2017
  42. AY M, Luo J, Langley M, Jin H, et al
    Molecular Mechanisms Underlying Protective Effects of Quercetin Against Mitochondrial Dysfunction and Progressive Dopaminergic Neurodegeneration in Cell Culture and MitoPark Transgenic Mouse Models of Parkinson's Disease.
    J Neurochem. 2017 Apr 4. doi: 10.1111/jnc.14033.
    PubMed     Abstract available


  43. KANNINEN KM, White AR
    Type-I interferons in Parkinson's disease: innate inflammatory response drives fate of neurons in model of degenerative brain disorder: An editorial comment on 'Type-I interferons mediate the neuroinflammatory response and neurotoxicity induced by rot
    J Neurochem. 2017;141:9-11.
    PubMed     Abstract available


    March 2017
  44. CRUCES-SANDE A, Mendez-Alvarez E, Soto-Otero R
    Copper increases the ability of 6-hydroxydopamine to generate oxidative stress and the ability of ascorbate and glutathione to potentiate this effect: potential implications in Parkinson's disease.
    J Neurochem. 2017 Mar 14. doi: 10.1111/jnc.14019.
    PubMed     Abstract available


  45. BECKER G, Mohamed Ali B, Michel A, Hustadt F, et al
    Comparative assessment of 6-[18 F]fluoro-L-m-tyrosine and 6-[18 F]fluoro-L-dopa to evaluate dopaminergic presynaptic integrity in a Parkinson's disease rat model.
    J Neurochem. 2017 Mar 10. doi: 10.1111/jnc.14016.
    PubMed     Abstract available


    February 2017
  46. ANDERSEN AD, Blaabjerg M, Binzer M, Kamal A, et al
    Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: Effect of L-DOPA treatment and changes in levodopa-induced dyskinesia.
    J Neurochem. 2017 Feb 28. doi: 10.1111/jnc.13997.
    PubMed     Abstract available


    January 2017
  47. FALKENBURGER B
    ExPPNing how acetylcholine improves gait in Parkinson's disease: An Editorial Highlight for 'Deletion of the Vesicular Acetylcholine Transporter from Pedunculopontine/laterodorsal tegmental neurons modifies gait'.
    J Neurochem. 2017 Jan 6. doi: 10.1111/jnc.13899.
    PubMed     Abstract available


    September 2016
  48. KOMNIG D, Schulz JB, Reich A, Falkenburger BH, et al
    Mice lacking Faim2 show increased cell death in the MPTP mouse model of Parkinson Disease.
    J Neurochem. 2016 Sep 17. doi: 10.1111/jnc.13847.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: